NCT06686628View on ClinicalTrials.gov

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 23, 2025

Study Completion Date

April 3, 2026

Conditions
Dermatitis Atopic
Interventions
DRUG

Amlitelimab

Pharmaceutical form: Injection solution Route of administration: SC injection

DRUG

Midazolam

Pharmaceutical form: Solution Route of administration: Oral

DRUG

Caffeine

Pharmaceutical form: Tablet Route of administration: Oral

DRUG

Metoprolol

Pharmaceutical form: Tablet Route of administration: Oral

DRUG

Omeprazole

Pharmaceutical form: Capsule Route of administration: Oral

DRUG

Warfarin

Pharmaceutical form: Tablet Route of administration: Oral

Trial Locations (1)

10117

Investigational Site Number : 2760001, Berlin

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06686628 - An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates | Biotech Hunter | Biotech Hunter